<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927702</url>
  </required_header>
  <id_info>
    <org_study_id>21-RES-001</org_study_id>
    <nct_id>NCT04927702</nct_id>
  </id_info>
  <brief_title>Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Lyophilized Acellular Fish Skin in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)</brief_title>
  <official_title>Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Lyophilized Acellular Fish Skin in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acera Surgical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acera Surgical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In participants with diabetic foot ulcers (DFUs), this study will assess complete wound&#xD;
      closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with lyophilized&#xD;
      acellular fish skin (Kerecis® Omega3 Wound).&#xD;
&#xD;
      In participants with venous leg ulcers (VLUs), this study will assess complete wound closure&#xD;
      by comparing synthetic hybrid-scale fiber matrix (Restrata®) with living cellular skin&#xD;
      substitute (Apligraf®)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For Participants With Diabetic Foot Ulcers, number of participants with 100 Percent Epithelialization (Closure) of Wound</measure>
    <time_frame>12 weeks</time_frame>
    <description>100 percent epithelialization of wound as assessed by a blinded evaluator via review of a three-dimensional high resolution photo of the wound plus confirmation of no drainage or need for additional dressing 2 weeks after 100 percent epithelialization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For Participants With Venous Leg Ulcers, number of participants with 100 Percent Epithelialization (Closure) of Wound</measure>
    <time_frame>16 weeks</time_frame>
    <description>100 percent epithelialization of wound as assessed by a blinded evaluator via review of a three-dimensional high resolution photo of the wound plus confirmation of no drainage or need for additional dressing 2 weeks after 100 percent epithelialization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Wound Area</measure>
    <time_frame>Weekly assessments for 12 weeks for DFU participants (16 weeks for VLU participants), or until 100 percent epithelialization, whichever occurs first.</time_frame>
    <description>Wound area measurements will be made via a three-dimensional high resolution photo of the wound with automated measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 100 Percent Epithelialization</measure>
    <time_frame>12 weeks for DFU participants (16 weeks for VLU participants), or until 100 percent epithelialization, whichever occurs first.</time_frame>
    <description>The number of weeks from initial application of study product until 100 percent epithelialization is first identified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Product Applications</measure>
    <time_frame>12 weeks for DFU participants (16 weeks for VLU participants), or until 100 percent epithelialization, whichever occurs first</time_frame>
    <description>The number of applications of study product until 100 percent epithelialization is first identified</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Score on SF-36 Questionnaire Measuring Quality of Life</measure>
    <time_frame>Day of initial product application and at either 12 weeks for DFU participants (16 weeks for VLU participants) or at 100 percent epithelialization (whichever occurs first)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pain Reported By Participant</measure>
    <time_frame>Day of initial product application and at either 12 weeks for DFU participants (16 weeks for VLU participants) or at 100 percent epithelialization (whichever occurs first)</time_frame>
    <description>The pain reported by the participant on a scale of 0 through 10 with 10 being the highest level of pain the participant has experienced</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Adverse Events Related to the Study Product and/or Procedure</measure>
    <time_frame>Up to six months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Investigator's Rating of the Ease of Use and Handling of Study Product</measure>
    <time_frame>12 weeks for DFU participants (16 weeks for VLU participants), or until 100 percent epithelialization, whichever occurs first</time_frame>
    <description>Investigator's rating of the ease of use and handling of the study product. Investigator will rate study product as &quot;very satisfied&quot;, &quot;satisfied&quot;, or &quot;not satisfied&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost Effectiveness</measure>
    <time_frame>12 weeks for DFU participants (16 weeks for VLU participants), or until 100 percent epithelialization, whichever occurs first</time_frame>
    <description>Total cost of study product applied to the participant</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with coverage of product by payor (insurance)</measure>
    <time_frame>12 weeks for DFU participants (16 weeks for VLU participants), or until 100 percent epithelialization, whichever occurs first</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biweekly (every 2 weeks) application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic Foot Ulcer Participants Assigned to Lyophilized Acellular Fish Skin (Kerecis® Omega3 Wound)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly application for either 12 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biweekly (every 2 weeks) application for either 16 weeks or until 100 percent epithelialization / wound closure (whichever occurs first)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synthetic Hybrid-Scale Fiber Matrix</intervention_name>
    <description>A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.</description>
    <arm_group_label>Diabetic Foot Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)</arm_group_label>
    <arm_group_label>Venous Leg Ulcer Participants Assigned to Synthetic Hybrid-Scale Fiber Matrix (Restrata®)</arm_group_label>
    <other_name>Restrata</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lyophilized Acellular Fish Skin</intervention_name>
    <description>An absorbable skin substitute comprised of intact North Atlantic Cod fish skin indicated for use in the local management of wounds.</description>
    <arm_group_label>Diabetic Foot Ulcer Participants Assigned to Lyophilized Acellular Fish Skin (Kerecis® Omega3 Wound)</arm_group_label>
    <other_name>Kerecis Omega3 Wound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Living Cellular Skin Substitute</intervention_name>
    <description>An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.</description>
    <arm_group_label>Venous Leg Ulcer Participants Assigned to Living Cellular Skin Substitute (Apligraf®)</arm_group_label>
    <other_name>Apligraf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Participants with Diabetic Foot Ulcers:&#xD;
&#xD;
          1. Participant is at least 18 years old&#xD;
&#xD;
          2. Participant is willing and capable of complying with all protocol requirements&#xD;
&#xD;
          3. Participant or legally authorized representative (LAR) is willing to provide written&#xD;
             informed consent&#xD;
&#xD;
          4. Participant has Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes&#xD;
             mellitus per American Diabetes Association)&#xD;
&#xD;
          5. Ulcer(s) must be located at least in part on the foot or ankle&#xD;
&#xD;
          6. Ulcer(s) must be present for more than 28 days prior to randomization and initial&#xD;
             application of study product, and has not adequately responded to conventional ulcer&#xD;
             therapy&#xD;
&#xD;
          7. Wound size must be &gt;1.0 cm^2 and &lt; 25 cm^2 on the day of randomization and initial&#xD;
             application of the study product, after initial debridement&#xD;
&#xD;
          8. Participant has adequate circulation to the affected extremity(ies), as demonstrated&#xD;
             by at least ONE of the following within 60 days prior to enrollment/randomization:&#xD;
&#xD;
               1. Dorsum transcutaneous oxygen test (TcPO2) of study leg(s) with results ≥40mmHg,&#xD;
                  OR&#xD;
&#xD;
               2. Ankle-Brachial Index (ABI) of study leg(s) with results of ≥ 0.7 and ≤ 1.3, OR&#xD;
&#xD;
               3. Toe-Brachial Index (TBI) of study extremity(ies) with results of ≥ 0.5&#xD;
&#xD;
        Exclusion Criteria for Participants with Diabetic Foot Ulcers:&#xD;
&#xD;
          1. Participant has been previously enrolled into this study, or is currently&#xD;
             participating in another prospective drug or device study that has not reached its&#xD;
             primary endpoint&#xD;
&#xD;
          2. Participant is pregnant, breast feeding or planning to become pregnant&#xD;
&#xD;
          3. Participant has a known allergy to resorbable suture materials, e.g. Polyglactin 910&#xD;
             (PGLA), Polydioxanone (PDS)&#xD;
&#xD;
          4. Participant has a known allergy to fish or fish material&#xD;
&#xD;
          5. Participant has a life expectancy less than six months as assessed by the investigator&#xD;
&#xD;
          6. Participant has received skin substitutes during the screening period or within 14&#xD;
             days prior to beginning of screening period&#xD;
&#xD;
          7. Participant has an additional wound within 3 cm of the study wound(s) or study wounds&#xD;
             are less than 3 cm apart&#xD;
&#xD;
          8. Hgb A1c &gt; 12 percent within 3 months prior to randomization&#xD;
&#xD;
          9. Participant not in reasonable metabolic control in the judgment of the investigator&#xD;
&#xD;
         10. Participant with a known history of poor compliance with medical treatments&#xD;
&#xD;
         11. Participant currently undergoing cancer treatment&#xD;
&#xD;
         12. Participant has been diagnosed with at least one of the following autoimmune&#xD;
             connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid&#xD;
             arthritis&#xD;
&#xD;
         13. Participant is taking parenteral corticosteroids or any cytotoxic agents for 7&#xD;
             consecutive days during the screening period or up to 30 days before the screening&#xD;
             period. Chronic oral steroid use is not excluded if dose is &lt; 10 mg per day for&#xD;
             prednisone.&#xD;
&#xD;
         14. Active infection, undrained abscess, or critical colonization of the wound(s) with&#xD;
             bacteria in the judgment of the investigator&#xD;
&#xD;
         15. Osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam&#xD;
             or radiographic evidence&#xD;
&#xD;
         16. Participant unwilling or unable to safely utilize appropriate offloading device to&#xD;
             unweight wound(s)&#xD;
&#xD;
         17. Study ulcer(s) experiences greater than 30 percent reduction over the 2-week screening&#xD;
             period&#xD;
&#xD;
         18. Participant also has a venous leg ulcer that is enrolled into this study&#xD;
&#xD;
        Inclusion Criteria for Participants with Venous Leg Ulcers:&#xD;
&#xD;
          1. Participant is at least 18 years old&#xD;
&#xD;
          2. Participant is willing and capable of complying with all protocol requirements&#xD;
&#xD;
          3. Participant or legally authorized representative (LAR) is willing to provide written&#xD;
             informed consent&#xD;
&#xD;
          4. Participant has peripheral venous disease per investigator judgment or diagnostic&#xD;
             confirmation&#xD;
&#xD;
          5. Ulcer(s) must be venous in origin, located on a lower extremity&#xD;
&#xD;
          6. Ulcer(s) must be present for more than 28 days prior to randomization and initial&#xD;
             application of study product, and has not adequately responded to conventional ulcer&#xD;
             therapy&#xD;
&#xD;
          7. Wound(s) size must be &gt;1.0 cm^2 and &lt; 50 cm^2 on the day of randomization and initial&#xD;
             application of the study product, after initial debridement&#xD;
&#xD;
          8. Participant has adequate circulation to the affected extremity(ies), as demonstrated&#xD;
             by at least ONE of the following within 60 days prior to enrollment/randomization:&#xD;
&#xD;
               1. Dorsum transcutaneous oxygen test (TcPO2) of study leg(s) with results ≥ 40mmHg,&#xD;
                  OR&#xD;
&#xD;
               2. Ankle-brachial index (ABI) of study leg(s) with results of ≥ 0.7 and ≤ 1.52, OR&#xD;
&#xD;
               3. Toe-Brachial Index (TBI) of study leg(s) with results of ≥ 0.5, OR&#xD;
&#xD;
               4. Doppler arterial waveforms, which are triphasic or biphasic at the ankle of the&#xD;
                  affected leg(s)&#xD;
&#xD;
        Exclusion Criteria for Participants with Venous Leg Ulcers:&#xD;
&#xD;
          1. Participant has been previously enrolled into this study, or is currently&#xD;
             participating in another prospective drug or device study that has not reached its&#xD;
             primary endpoint&#xD;
&#xD;
          2. Participant is pregnant, breast feeding or planning to become pregnant&#xD;
&#xD;
          3. Participant has a known allergy to resorbable suture materials, e.g. Polyglactin 910&#xD;
             (PGLA), Polydioxanone (PDS)&#xD;
&#xD;
          4. Participant has a known allergy to bovine materials or agarose shipping materials&#xD;
&#xD;
          5. Participant has a life expectancy less than six months as assessed by the investigator&#xD;
&#xD;
          6. Participant has received skin substitutes during the screening period or within 14&#xD;
             days prior to the beginning of the screening period&#xD;
&#xD;
          7. Participant has an additional wound within 3 cm of the study wound or study wounds are&#xD;
             less than 3 cm apart&#xD;
&#xD;
          8. Hgb A1c &gt; 12 percent within 3 months prior to randomization in patients with a known&#xD;
             history of diabetes&#xD;
&#xD;
          9. Participant is not in reasonable metabolic control in the judgment of the investigator&#xD;
&#xD;
         10. Participant has a known history of poor compliance with medical treatments&#xD;
&#xD;
         11. Participant currently undergoing cancer treatment&#xD;
&#xD;
         12. Participant has been diagnosed with at least one of the following autoimmune&#xD;
             connective tissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoid&#xD;
             arthritis&#xD;
&#xD;
         13. Participant is taking parenteral corticosteroids or any cytotoxic agents for 7&#xD;
             consecutive days during the screening period or up to 30 days before the screening&#xD;
             period. Chronic oral steroid use is not excluded if dose is &lt; 10 mg per day for&#xD;
             prednisone.&#xD;
&#xD;
         14. Active infection, undrained abscess, or critical colonization of the wound(s) with&#xD;
             bacteria in the judgment of the investigator&#xD;
&#xD;
         15. Participant unwilling or unable to tolerate use of compression therapy for the&#xD;
             duration of the study&#xD;
&#xD;
         16. Study ulcer(s) experiences greater than 30 percent reduction over the 2-week run-in&#xD;
             period&#xD;
&#xD;
         17. Participant also has a diabetic foot ulcer that is enrolled into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chief Science Officer</last_name>
    <phone>844-879-2237</phone>
    <email>macewan@acera-surgical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Hewitt, DPM</last_name>
      <phone>303-724-4298</phone>
      <email>michael.a.hewitt@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Garrett Moore, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Johnson</last_name>
      <phone>312-942-1735</phone>
      <email>matthew_johnson@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Thea P Price, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Physicians Clinic</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DruAnne McMartin</last_name>
      <phone>402-354-0350</phone>
      <email>dru.mcmartin@nmhs.org</email>
    </contact>
    <investigator>
      <last_name>John M Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zachary Gortler</last_name>
      <phone>919-843-1268</phone>
      <email>zachary_gortler@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>William Marston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gundersen Health System</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Halverson</last_name>
      <phone>608-775-0852</phone>
      <email>kehalver@gundersenhealth.org</email>
    </contact>
    <investigator>
      <last_name>Bradley P Abicht, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

